ArticleScientific reports2025
Design synthesis, characterization, molecular docking and antimicrobial evaluation of novel heterocycles with acrylonitrile and anthracene moieties.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Design, synthesis, and insecticidal potency of novel 3-methyl-pyrazole derivatives against Culex pipiens larvae.Scientific reports · 2026Article
- Transformation of 3-(4-methoxybenzylidine)-5-(RSC advances · 2026Article
- Synthesis and radiolabelled evaluation of novel pyrimidine derivatives as dual α-amylase inhibitors and GIT-targeted molecular imaging probe.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The synthon 3-(anthracen-9-yl)-2-cyanoacryloyl chloride 4 was produced and exploited in the creation of a wide variety of highly reactive heterocyclic compounds, by its interaction with diverse nitrogen nucleophiles. Using spectral and elemental analysis, the structures of each synthesized heterocycles were fully investigated. Ten of the thirteen novel heterocycles showed encouraging efficacy against antibiotic-resistant bacteria (MRSA). Among these, compounds 6, 7, 10, 13b, and 14 demonstrated the highest antibacterial activity, showing inhibition zones near 4 cm. However, molecular docking studies revealed varied binding affinities for Penicillin-Binding Protein 2a (PBP2a), a crucial target in MRSA resistance. Some compounds, such as 7, 10, and 14, displayed higher binding affinities and interaction stability within the PBP2a active site compared to the co-crystallized quinazolinone ligand. In contrast, compounds 6 and 13b exhibited lower docking scores but still showed substantial antimicrobial activity, with 6 showing the lowest MIC (9.7 μg/100 μL) and MBC (78.125 μg/100 μL) values. The docking analysis revealed key interactions, including hydrogen bonding and π-stacking, particularly with residues like Lys 273, Lys 316, and Arg 298, which were identified as interacting with the co-crystallized ligand within the crystal structure of PBP2a. These residues are essential for the enzymatic activity of PBP2a. These findings suggest that the synthesized compounds could serve as promising anti-MRSA agents, highlighting the importance of integrating molecular docking with biological assays to identify effective therapeutic candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.